Denali Therapeutics Inc [DNLI] stock is trading at $16.99, up 1.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNLI shares have gain 1.07% over the last week, with a monthly amount drifted -10.25%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Denali Therapeutics Inc [NASDAQ: DNLI] stock has seen the most recent analyst activity on April 10, 2025, when Cantor Fitzgerald upgraded its rating to an Overweight. On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $31 on the stock. Robert W. Baird started tracking the stock assigning an Outperform rating and suggested a price target of $31 on January 07, 2025. William Blair initiated its recommendation with an Outperform. Stifel upgraded its rating to Buy for this stock on December 16, 2024, but kept the price target unchanged to $37.
Denali Therapeutics Inc [DNLI] stock has fluctuated between $10.57 and $24.34 over the past year. Currently, Wall Street analysts expect the stock to reach $33.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $16.99 at the most recent close of the market. An investor can expect a potential return of 97.17% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.46 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.79 points at the first support level, and at 16.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.12, and for the 2nd resistance point, it is at 17.24.
Ratios To Look Out For
For context, Denali Therapeutics Inc’s Current Ratio is 9.79. On the other hand, the Quick Ratio is 9.79, and the Cash Ratio is 1.01.
Transactions by insiders
Recent insider trading involved CAROLE HO, Officer, that happened on Dec 04 ’25 when 1882.0 shares were purchased. COFO and Secretary, Schuth Alexander O. completed a deal on Aug 12 ’25 to sell 2937.0 shares. Meanwhile, Chief Medical Officer Ho Carole sold 2937.0 shares on Aug 12 ’25.
